# Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

Study · id `cardio:ct-nct03463317` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03463317](<https://clinicaltrials.gov/study/NCT03463317>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03463317

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 912 participants.

## Technical summary

Registry record NCT03463317. Randomized; no masking; primary purpose prevention. Start 2018-02-28 (actual); primary completion 2024-11-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 912 participants (enrolled count; ClinicalTrials.gov record NCT03463317, source copy `cardio:ctgov-nct03463317-2025-12-12`, retrieved 2026-10-26)
- Started: 2018-02-28 (actual) (ClinicalTrials.gov record NCT03463317, source copy `cardio:ctgov-nct03463317-2025-12-12`, retrieved 2026-10-26)
- Primary completion: 2024-11-30 (actual) (ClinicalTrials.gov record NCT03463317, source copy `cardio:ctgov-nct03463317-2025-12-12`, retrieved 2026-10-26)
- Completion: 2024-11-30 (actual) (ClinicalTrials.gov record NCT03463317, source copy `cardio:ctgov-nct03463317-2025-12-12`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT03463317, source copy `cardio:ctgov-nct03463317-2025-12-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03463317-2025-12-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
- Acronym: CLOSURE-AF
- Condition: Atrial Fibrillation
- Intervention (Device): CE-mark approved LAA closure devices
- Intervention (Drug): Acetylsalicylic acid
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Dabigatran
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): Apixaban
- Intervention (Drug): Edoxaban
- Intervention (Drug): Phenprocoumon
- Intervention (Drug): Warfarin
- Lead sponsor: Charite University, Berlin, Germany
- Lead sponsor class: OTHER
- Collaborator: Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
- Collaborator class: OTHER
- Collaborator: Atrial Fibrillation Network
- Collaborator class: OTHER
- Collaborator: Stiftung Institut fuer Herzinfarktforschung
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention name matches this record: Dabigatran (`cardio:dabigatran`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry intervention name matches this record: Edoxaban (`cardio:edoxaban`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: Charite University, Berlin, Germany (`cardio:org-charite-university-berlin-germany`)
- Registry lists this organization as a collaborator: Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) (`cardio:org-deutsches-zentrum-fur-herz-kreislauf-forschung-dzhk`)
- Registry lists this organization as a collaborator: Atrial Fibrillation Network (`cardio:org-atrial-fibrillation-network`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation (`cardio:pubmed-41849741`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 14b00ee304e8089ea74a001ded804e8737b250cb688fca853ba9dcd59d5d5366
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
